Perillyl Alcohol Drug Interactions, Uses, Effectiveness, Safety & More
What is this page for?
First and foremost: how Perillyl Alcohol interacts with medications. The heart of this page is the interaction list — every drug Perillyl Alcohol is known to interact with, and how serious each one is.
But these pages have grown well beyond that into a full monograph — what Perillyl Alcohol is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy
Check Perillyl Alcohol against your medication
Add one medicationDrugs that interact with Perillyl Alcohol
0 medications have a known interaction with Perillyl Alcohol, graded by severity. Select any drug for the full evidence-based detail.
We don’t currently list any known drug interactions for Perillyl Alcohol. This doesn’t guarantee none exist — always confirm with your pharmacist before combining supplements with your medications.
What Severity, Likelihood & Evidence Mean
Severity — How Serious It Can Be
- Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
- Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
- Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
- No known interaction. Checked against our sources with nothing documented — not the same as proven safety.
Likelihood — How Well It’s Documented
- Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
- Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
- Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
- Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.
Where This Data Comes From
- Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
- Each drug listed above links to the full report for that exact Perillyl Alcohol combination — clinical detail, likelihood, evidence level, and citations.
- Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Perillyl Alcohol: Uses, Safety & Side Effects
Perillyl alcohol is a natural compound found in the essential oils of plants like mint, lavender, and citrus, and it has mainly been studied as an experimental anti-cancer agent rather than as an everyday supplement. The evidence in people is limited and still under investigation, so it should not be used to treat or prevent any disease without medical supervision. Talk to your pharmacist or doctor before trying it.
- Part used
- Naturally found in the essential oils of plants such as lavender, peppermint, sage, cherries, and citrus fruits; often produced from limonene
- Common forms
- Capsules, oral liquid, and (in research settings) intranasal preparations
- Cancer research (investigational)
- Antioxidant interest
- General wellness supplement
- Aromatherapy-related products
Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.
It is mostly an investigational compound with limited human safety data outside clinical trials.
Insufficient reliable information available; avoid using.
Read the full pregnancy detailInsufficient reliable information available; avoid using.
Read the full breastfeeding detailPregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Overview
Perillyl alcohol is a naturally occurring compound called a monoterpene. It is found in small amounts in the essential oils of many common plants, including lavender, peppermint, sage, spearmint, cherries, and citrus fruits. It is closely related to another plant compound called limonene, and it is often made from limonene in the laboratory.
Unlike many herbs that have a long history of traditional use, perillyl alcohol is best known as a research chemical. Scientists have studied it mainly as a possible anti-cancer agent. Because of this, it is not a typical everyday dietary supplement, and most of what is known about it comes from laboratory studies, animal studies, and early clinical trials.
How it works
Perillyl alcohol is a monoterpene, a type of compound that gives many plants their scent. In laboratory and animal studies, researchers have proposed several ways it might act. These include interfering with signals that tell cancer cells to grow, encouraging damaged cells to die in a controlled way (apoptosis), and affecting certain enzymes involved in cell growth.
It is worth stressing that most of these mechanisms come from cell and animal research. What happens in a laboratory dish does not always translate to the same effect in the human body. The exact way it works in people, and whether those effects are strong enough to be useful, is still being studied.
Does Perillyl Alcohol work?
How to read these evidence grades
Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.
For Perillyl Alcohol, current evidence isn’t strong enough to rate any specific use. The conditions it has been studied for are listed below.
Also studied for 6 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Actinic keratoses
Preliminary clinical research shows that applying perillyl alcohol 0.3% or 0.76% topically twice daily for 3 months does not improve actinic keratoses based on histopathological analysis.
Insufficient Reliable Evidence To Rate Brain tumor
Preliminary clinical research in patients with recurrent malignant gliomas shows that receiving perillyl alcohol 0.3% v/v (55 mg) intranasally four times daily for 6 months following surgery, chemotherapy, and radiation is associated with 6-month progression-free survival in 48% of patients with glioblastoma multiforme, 60% of patients with grade III astrocytoma, and 67% of patients with anaplastic oligodendroglioma. A similar and very small clinical study in 12 adults with recurrent glioblastoma refractory to radiation and temozolomide shows that receiving highly purified (>99%) perillyl alcohol at doses ranging from 96-288 mg intranasally four times daily for 6 months is associated with 6-month progression-free survival in 4 patients and a median overall survival of 15 months. Lack of a comparator group in both studies limits the validity of these results.
Insufficient Reliable Evidence To Rate Breast cancer
Preliminary clinical research shows that taking perillyl alcohol 1200-1500 mg/m2 orally four times daily does not improve survival in women with advanced treatment-refractory breast cancer. Adverse effects limited the planned duration of the study.
Insufficient Reliable Evidence To Rate Colorectal cancer
Preliminary clinical research shows that taking perillyl alcohol 1200-1600 mg/m2 orally four times daily does not reduce the time until disease progression in patients with metastatic colorectal adenocarcinoma.
Insufficient Reliable Evidence To Rate Ovarian cancer
Preliminary clinical research shows that taking perillyl alcohol 1200-1500 mg/m2 orally four times daily does not reduce disease progression or improve overall survival in patients with advanced ovarian cancer.
Insufficient Reliable Evidence To Rate Prostate cancer
A preliminary clinical trial shows that taking perillyl alcohol does not decrease prostate cancer progression in patients with advanced hormone-refractory prostate cancer. There was a high dropout rate due to intolerable side effects.
Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.
Safety & precautions
Because perillyl alcohol has mainly been used in research and clinical trials, there is limited information on its long-term safety as a general supplement. People in studies have generally tolerated it, but side effects have been reported, and the doses used in trials are carefully controlled by medical teams.
People with cancer or other serious health conditions should never use perillyl alcohol on their own to treat their illness. If you are interested in it, do so only under the guidance of a doctor, ideally within a supervised setting.
Pregnancy and breastfeeding: There is not enough reliable safety information for these groups. To be safe, it should be avoided during pregnancy and while breastfeeding.
Anyone considering this compound should talk with a pharmacist or doctor first, especially if you take prescription medicines or have an ongoing medical condition.
Side effects
In studies where perillyl alcohol was taken by mouth, the most commonly reported side effects involved the stomach and gut, such as nausea, vomiting, fullness, and an unpleasant taste. Some people also reported tiredness or general discomfort.
When breathed in through the nose in research settings, it has been linked to nasal irritation. Because it is an oil-related compound, it may cause irritation if it contacts the skin or eyes directly.
Serious side effects are not well characterized outside of clinical trials. If you experience any concerning symptoms while using a product containing perillyl alcohol, stop and contact a healthcare provider.
Perillyl Alcohol: Reported Adverse Effects
Documented safety reports on Perillyl Alcohol from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.
Orally, perillyl alcohol can cause adverse effects including gastrointestinal upset, reflux, nausea, diarrhea or constipation, fatigue, and headache. In high doses, perillyl alcohol has been associated with single reports of acute pancreatitis, increased bilirubin, increased white blood cell count, and hypokalemia.
Topically, perillyl alcohol has been rarely reported to cause a mild rash or tenderness. Intranasally, perillyl alcohol has been associated with nasal soreness or itching, runny nose, skin irritation, or headache.
- Bailey HH, Wilding G, Tutsch KD, et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 2004;54:368-76.
- Stearns V, Coop A, Singh B, et al. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 2004;10:7583-91.
- Morgan-Meadows S, Dubey S, Gould M, et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003;52:361-6.
- Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003;21:367-72.
- Ripple, G. H., Gould, M. N., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Simon, K., Binger, K., Tutsch, K. D., Pomplun, M., Wahamaki, A., Marnocha, R., Wilding, G., and Bailey, H. H. Phase I clinical and pharmacokinetic study of perillyl alcohol adm
- Ripple GH, Gould MN, Stewart JA, and et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998;4(5):1159-1164.
- Hudes, G. R., Szarka, C. E., Adams, A., Ranganathan, S., McCauley, R. A., Weiner, L. M., Langer, C. J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., and Gallo, J. M. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refract
- Bailey, H. H., Levy, D., Harris, L. S., Schink, J. C., Foss, F., Beatty, P., and Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol.Oncol. 2002;85(3):464-
- Murren, J. R., Pizzorno, G., DiStasio, S. A., McKeon, A., Peccerillo, K., Gollerkari, A., McMurray, W., Burtness, B. A., Rutherford, T., Li, X., Ho, P. T., and Sartorelli, A. Phase I study of perillyl alcohol in patients with refractory malignancies. Canc
- Azzoli, C. G., Miller, V. A., Ng, K. K., Krug, L. M., Spriggs, D. R., Tong, W. P., Riedel, E. R., and Kris, M. G. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother.Pharmacol. 2003;51(6):493-498.
- Meadows, S. M., Mulkerin, D., Berlin, J., Bailey, H., Kolesar, J., Warren, D., and Thomas, J. P. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest.Cancer 2002;32(2-3):125-128.
- Matos JM, Schmidt CM, Thomas HJ, et al. A pilot study of perillyl alcohol in pancreatic cancer. J Surg Res. 2008;147(2):194-9.
- Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(1):149-57.
- Stratton SP, Alberts DS, Einspahr JG, et al. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila). 2010;3(2):160-9.
- Stratton SP, Saboda KL, Myrdal PB, et al. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer. 2008;60(3):325-30.
- Schönthal AH, Peereboom DM, Wagle N, et al. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv 2021;3(1):vdab005.
Cluster headache Neurologic/CNS
Orally, perillyl alcohol in high doses (at least 1.2 grams/m2 four times daily) can cause significant adverse effects including fatigue and headache. Intranasally, perillyl alcohol has been associated with headaches.
- Bailey HH, Wilding G, Tutsch KD, et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 2004;54:368-76.
- Stearns V, Coop A, Singh B, et al. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 2004;10:7583-91.
- Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003;21:367-72.
- Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(1):149-57.
- Schönthal AH, Peereboom DM, Wagle N, et al. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv 2021;3(1):vdab005.
Constipation Gastrointestinal
Orally, perillyl alcohol can cause gastrointestinal upset, reflux, nausea, vomiting, lack of appetite, bloating, belting, heartburn, diarrhea, or constipation. Some side effects appear to be dose related. Higher doses are more likely to cause gastrointestinal upset such as reflux. There is a single report of acute pancreatitis in a patient taking perillyl alcohol in high doses (at least 1.2 grams/m2 four times daily). Some researchers speculate that intermittent administration of perillyl alcohol might be better tolerated than continuous administration; however, in one trial, intermittent administration did not reduce side effects compared to continuous administration.
- Bailey HH, Wilding G, Tutsch KD, et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 2004;54:368-76.
- Stearns V, Coop A, Singh B, et al. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 2004;10:7583-91.
- Morgan-Meadows S, Dubey S, Gould M, et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003;52:361-6.
- Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003;21:367-72.
- Ripple, G. H., Gould, M. N., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Simon, K., Binger, K., Tutsch, K. D., Pomplun, M., Wahamaki, A., Marnocha, R., Wilding, G., and Bailey, H. H. Phase I clinical and pharmacokinetic study of perillyl alcohol adm
- Ripple GH, Gould MN, Stewart JA, and et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998;4(5):1159-1164.
- Hudes, G. R., Szarka, C. E., Adams, A., Ranganathan, S., McCauley, R. A., Weiner, L. M., Langer, C. J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., and Gallo, J. M. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refract
- Bailey, H. H., Levy, D., Harris, L. S., Schink, J. C., Foss, F., Beatty, P., and Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol.Oncol. 2002;85(3):464-
- Murren, J. R., Pizzorno, G., DiStasio, S. A., McKeon, A., Peccerillo, K., Gollerkari, A., McMurray, W., Burtness, B. A., Rutherford, T., Li, X., Ho, P. T., and Sartorelli, A. Phase I study of perillyl alcohol in patients with refractory malignancies. Canc
- Azzoli, C. G., Miller, V. A., Ng, K. K., Krug, L. M., Spriggs, D. R., Tong, W. P., Riedel, E. R., and Kris, M. G. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother.Pharmacol. 2003;51(6):493-498.
- Meadows, S. M., Mulkerin, D., Berlin, J., Bailey, H., Kolesar, J., Warren, D., and Thomas, J. P. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest.Cancer 2002;32(2-3):125-128.
- Matos JM, Schmidt CM, Thomas HJ, et al. A pilot study of perillyl alcohol in pancreatic cancer. J Surg Res. 2008;147(2):194-9.
- Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(1):149-57.
Hypokalemia Endocrine
Use of high doses of perillyl alcohol orally can cause potassium depletion leading to hypokalemia.
- Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003;21:367-72.
- Granath J, Ingvarsson S, von Thiele U, Lundberg U. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther 2006;35:3-10.
- Hudes, G. R., Szarka, C. E., Adams, A., Ranganathan, S., McCauley, R. A., Weiner, L. M., Langer, C. J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., and Gallo, J. M. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refract
Skin irritation Pulmonary/Respiratory
Intranasally, perillyl alcohol has been associated with nasal soreness or itching, runny nose, and skin irritation.
Adverse-effects data: Natural Medicines, Therapeutic Research Center
Dosing
There is no established standard supplement dose of perillyl alcohol for the general public. The doses used in research were chosen for clinical trials and were given under close medical supervision, so they do not apply to over-the-counter use.
If you choose to use a product that contains perillyl alcohol, follow the directions on the product label and do not exceed them. Because product quality and strength can vary, and because this compound is mainly investigational, it is wise to check with a pharmacist or doctor before starting.
Perillyl Alcohol & Pregnancy
Perillyl Alcohol & Breastfeeding
© 2026 Therapeutic Research Center
Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center
References & further reading
The 18 references that drive our Perillyl Alcohol monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Bailey HH, Wilding G, Tutsch KD, et al. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol 2004;54:368-76. PubMed
- Stearns V, Coop A, Singh B, et al. A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res 2004;10:7583-91. PubMed
- Morgan-Meadows S, Dubey S, Gould M, et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003;52:361-6. PubMed
- Liu G, Oettel K, Bailey H, et al. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs 2003;21:367-72. PubMed
- Granath J, Ingvarsson S, von Thiele U, Lundberg U. Stress management: a randomized study of cognitive behavioural therapy and yoga. Cogn Behav Ther 2006;35:3-10. PubMed
- Ripple, G. H., Gould, M. N., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Simon, K., Binger, K., Tutsch, K. D., Pomplun, M., Wahamaki, A., Marnocha, R., Wilding, G., and Bailey, H. H. Phase I clinical and pharmacokinetic study of perillyl alcohol adm
- Ripple GH, Gould MN, Stewart JA, and et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998;4(5):1159-1164.
- Hudes, G. R., Szarka, C. E., Adams, A., Ranganathan, S., McCauley, R. A., Weiner, L. M., Langer, C. J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., and Gallo, J. M. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refract
- Bailey, H. H., Levy, D., Harris, L. S., Schink, J. C., Foss, F., Beatty, P., and Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96. Gynecol.Oncol. 2002;85(3):464- PubMed
- Murren, J. R., Pizzorno, G., DiStasio, S. A., McKeon, A., Peccerillo, K., Gollerkari, A., McMurray, W., Burtness, B. A., Rutherford, T., Li, X., Ho, P. T., and Sartorelli, A. Phase I study of perillyl alcohol in patients with refractory malignancies. Canc PubMed
- Azzoli, C. G., Miller, V. A., Ng, K. K., Krug, L. M., Spriggs, D. R., Tong, W. P., Riedel, E. R., and Kris, M. G. A phase I trial of perillyl alcohol in patients with advanced solid tumors. Cancer Chemother.Pharmacol. 2003;51(6):493-498. PubMed
- Meadows, S. M., Mulkerin, D., Berlin, J., Bailey, H., Kolesar, J., Warren, D., and Thomas, J. P. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest.Cancer 2002;32(2-3):125-128. PubMed
- Stratton SP, Alberts DS, Einspahr JG, et al. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila). 2010;3(2):160-9. PubMed
- da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz). 2008;56(4):267-76. PubMed
- Stratton SP, Saboda KL, Myrdal PB, et al. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer. 2008;60(3):325-30. PubMed
- Matos JM, Schmidt CM, Thomas HJ, et al. A pilot study of perillyl alcohol in pancreatic cancer. J Surg Res. 2008;147(2):194-9. PubMed
- Bailey HH, Attia S, Love RR, et al. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008;62(1):149-57. PubMed
- Schönthal AH, Peereboom DM, Wagle N, et al. Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. Neurooncol Adv 2021;3(1):vdab005. PubMed
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Perillyl Alcohol: Common Questions
What is Perillyl Alcohol used for, and does it work?
Does Perillyl Alcohol interact with prescription medications?
How are Perillyl Alcohol interactions rated?
Is it safe to take Perillyl Alcohol with my medications?
Where does this Perillyl Alcohol interaction information come from?
What is Perillyl Alcohol used for?
Is Perillyl Alcohol natural?
Is Perillyl Alcohol safe to take?
Can I use it instead of my cancer treatment?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Have a question about Perillyl Alcohol?
Our pharmacists answer your medication & supplement questions — free.